GILEAD | Medical Information

Livdelzi ® (seladelpar) Treatment Interruption/Adherence

This document is in response to your request for information regarding Livdelzi® (seladelpar [SEL]) and the effect of adherence or treatment interruption on efficacy outcomes.

Some data may be outside of the US FDA-approved prescribing information. In providing this data, Gilead Sciences, Inc. is not making any representation as to its clinical relevance or to the use of any Gilead product(s). For information about the approved conditions of use of any Gilead drug product, please consult the FDA-approved prescribing information.

The full indication, important safety information, and boxed warnings are available at: www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.

Product Labeling[1]

The recommended dosage of SEL is 10 mg orally once daily. Administer SEL with or without food.

Available Data on SEL Adherence or Treatment Interruption

Administration of SEL and Management of Missed Doses[2]

Patients should take 1 capsule orally, every day, at approximately the same time each day.

Patients should take the missed dose up to a maximum of 8 hours after the time they should have taken it. If >8 hours have passed, patients should skip the dose and resume normal dosing the next day.

Literature Search

Additionally, a literature search was conducted in Ovid MEDLINE and Embase databases for studies published up to January 22, 2026, using search terms that included Livdelzi, seladelpar, treatment adherence, treatment interruption, and related search terms. No relevant citations were found.

References

1. Enclosed. LIVDELZI® (seladelpar) capsules, for oral use. US Prescribing Information. Foster City, CA.
2. Gilead Sciences Inc. Data on File.

Product Label

For the full indication, important safety information, and boxed warning(s), please refer to the Livdelzi US Prescribing Information available at: www.gilead.com/-/media/files/pdfs/medicines/pbc/livdelzi/livdelzi_pi.

Follow-Up

For any additional questions, please contact Gilead Medical Information at:

☎ 1-866-MEDI-GSI (1-866-633-4474) or 🖱 www.askgileadmedical.com

Adverse Event Reporting

Please report all adverse events to:

Gilead Global Patient Safety ☎ 1-800-445-3235, option 3 or
🖱 www.gilead.com/utility/contact/report-an-adverse-event

FDA MedWatch Program by ☎ 1-800-FDA-1088 or ✉MedWatch, FDA, 5600 Fishers Ln, Rockville, MD 20852 or 🖱 www.accessdata.fda.gov/scripts/medwatch

Data Privacy

The Medical Information service at Gilead Sciences may collect, store, and use your personal information to provide a response to your medical request. We may share your information with other Gilead Sciences colleagues to ensure that your request is addressed appropriately. If you report an adverse event or concern about the quality of a Gilead or Kite product, we will need to use the information you have given us in order to meet our regulatory requirements in relation to the safety of our medicines.

It may be necessary for us to share your information with Gilead's affiliates, business partners, service providers, and regulatory authorities located in countries besides your own. Gilead Sciences has implemented measures to protect the personal information you provide. Please see the Gilead Privacy Statement (www.gilead.com/privacy-statements) for more information about how Gilead handles your personal information and your rights. If you have any further questions about the use of your personal information, please contact gilead.privacy@gilead.com.